News
Valneva shares tumble after suspension of US chikungunya vaccine licence
Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the licence for its chikungunya vaccine, Ixchiq, with immediate effect, citing serious safety concerns.
Valneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.
Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly 22% lower ahead of the morning bell at $9.09.
FDA does a 180, suspending use of Valneva's chikungunya vaccine
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States. | Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq,
The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...
Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...
TipRanks on MSN3d
Valneva SE (ADR) trading halted, news pending
SE (ADR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback